Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Sponsor: Eisai Inc.
Terminated
evolving standard of care and difficulties of enrolling participants
Other terminated trials from Eisai Inc.
- Recurrent Hepatocellular Carcinoma · May 2025
- Epilepsies, Myoclonic · Phase PHASE3 · Aug 2024
- Catamenial Epilepsy · Phase PHASE4 · Dec 2023
- Epilepsy · Phase PHASE4 · May 2023
- Amyotrophic Lateral Sclerosis · Phase NA · Feb 2023
More terminations from Eisai Inc.
Other Metastatic Breast Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Metastatic Breast Cancer and is currently terminated or withdrawn. Eisai Inc. leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Unknown Status → Terminated
▶ Show 10 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — Apr 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2017 — Jan 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
- Halozyme Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .